Aptamer Share Discussion Threads

[amaretto1] 12/2/2024 19:31

Every on scroll back a few weeks On this clown Moron

[icac] 12/2/2024 18:29

nothing new. it's on bbc.co.uk.
NHS has delayed drugs for alzhimer patience for 2 years.
I see that as bad news aptamer. 2 years????? how Manny raise will that be??

[amaretto1] 12/2/2024 18:21

8 pm tonight's Panorama On Alzheimer's !

[amaretto1] 12/2/2024 18:10

One News drop here Will change everything And it won't be placing news Update on Alzheimer due very soon !!

[amaretto1] 12/2/2024 18:09

U mean HE1 that 10 bagged ? Or SDL that 4 bagged ? Or getting tfo of AGL at 37 pence That's all this yearAnd your wins please bones Educate the thread

[bones698] 12/2/2024 08:57

You can't half pick em amaretto lol

[icac] 09/2/2024 11:46

next RNs , due to the lack of interest and deals at advanced stage unable to conclude, therefore we have to raise £3.6m ( 12 month running cost) at 30-50% discount price.

[amaretto1] 09/2/2024 11:37

Dummies playing big boy games ! Wait for next RNS

[icac] 09/2/2024 10:35

amaretto, go and read the LSE board.
are they also child over there ?

[icac] 09/2/2024 10:09

share price fallen from over £1 to 0.7p.. how can you still back the product/service aptamer provide??

[icac] 09/2/2024 09:51

the only thing that is embarrassing itself is the company released RNS and your continue support for the next gamechanger RNS . you said the same thing back in October/ novemebr. it aren't going to happen. lol

[amaretto1] 09/2/2024 09:35

U silly child Go away Your embarrassing yourself

[amaretto1] 09/2/2024 06:07

Oh shut up u clown I'm pretty sure when you have bought back in It's going to 5 pence !! Wait for the next news drop longs

[icac] 08/2/2024 17:53

share price may seem low at current level, you could buy in at 0.70p , few months down the line they could raise at 0.35p , 50% down on whatever amount you invested..
doesn't look very attractive at all does it??

[icac] 08/2/2024 17:43

bones, this tech was meant to replace antibodies, antibodies had been proven to be safe for many years.. most pharmaceutical companies not taking risk of their company reputation for something that is only a fraction cheaper.

just like car parts, mobile wafers etc etc..

so now we see every year , aptama might get 1 or 2 pharmas on board, but at that rate it is not enough to cover wages and other overheads, resulting in raise after raise..

I cannot see how they can cha ge it around..

[icac] 08/2/2024 17:35

in regard with FAB, I did not go and invest . but did start to do some research into the company.. in my watchlist

[icac] 08/2/2024 17:34

most Aim companies always over promise, that's the only way they can suck in investors to invest.. annual profit and loss account do not lie, that's when investors can see the true colour of a company.

[bones698] 08/2/2024 17:11

Nobody wants to spend money and do deals meaning the really small companies get hammered even if they have good tech . Sadly this will see another dillutive placing later this year imo probably 0.5p or below

[porky9] 08/2/2024 05:18

@ICAC
FAB was at the recent pro active pitching event, highly likely they will place to bolster cash soon before it starts to move forward why attend a pitching event otherwise. Long evaluation period with NCI before that can pay off IMO and they don't directly financially benefit either from it anyhow as NCI have all the ownership rights should they strike success. Not convinced it was that great a deal frankly.

APTA - not sure why sales revenue are continuing to decline, was shocked the invoiced revenue was as low as it is, just £300k in six months. Trying to get my head around the actual sales process from signed order to actual invoice. In most businesses i have been involved with there is normally a raised invoice for at least a deposit on a signed order. With APTA they say we hope to process a signed order " subject to target material being delivered by customers in a timely manner and scientific attrition" so based on the actual declared revenue and that statement it feels like nothing is actually invoiced until the customer comes to them with material to work on?. So does that mean if the client pulls out and doesn't want to continue they just don't deliver the material? Is it like signing a contract that a company can supply you but later you don't actually order anything? Anyone here have any ideas, looks odd to me?

So they did £4m of revenue in 2022 which crashed to £1.75m in 2023 (£1m H1/£750k H2)and burnt out after spending millions of SH money and after the restructure pledged to get cash burn under £3.5m a year and with this amazing pipeline were forecasting a recovery to £3m of revenue. To then invoice a mere £300k for H1 (70% down on H1 23)it did take me by surprise i have to say.

Is it just me or does it feel like AIM currently is full of businesses over promising on what they can deliver?

[icac] 06/2/2024 10:53

fab will switch to FAB now

[cbeadle] 06/2/2024 10:27

Switch to FAB , agreement with NCI and deals starting to happen

[icac] 05/2/2024 17:19

biotech is always going to be high risk and high return.
so far, not a very good business. losing investors lots of money each day.

[bones698] 05/2/2024 16:30

And some gold for decades but lose money . I'm not seeing a compelling case here . They need to sign some big deals otherwise it's another fund raise . Deal sizes are quite small even with the big players so I see a struggle ahead for apt and it's sales team .

Already now trading well below he last fund raise price progress has been slow and they are burning through the cash quickly .